What is trastuzumab deruxtecan's activity for patients with CNS+ disease?

The DESTINY-Breast04 trial excluded patients with active CNS metastases so the study does not provide information on the activity of this drug in HER2-low CNS disease. In HER2-positive disease, however, CNS activity has been observed with trastuzumab deruxtecan; among patients evaluated for CNS resp...

In HER2 amplified patients with stable brain metastasis, T-DXd was associated with similar PFS compared to those without brain metastasis in the DESTINY-Breast03, therefore suggesting activity of T-DXd in brain mets.

Drug-antibody conjugates do have the ability to cross blood brain barrier and Trastuzumab-deruxtecan (T-DXd) has shown impressive intracranial activity across multiple studies.

A subgroup analysis of 24 patients with brain metastases in DESTINY-Breast 01, reported intracranial objective response of ...